{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:32:55Z","timestamp":1786980775000,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s10549-022-06723-z","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T02:12:57Z","timestamp":1662948777000},"page":"355-361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cancer risks associated with heterozygous ATM loss of function and missense pathogenic variants based on multigene panel analysis"],"prefix":"10.1007","volume":"196","author":[{"given":"Yael","family":"Laitman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinat","family":"Bernstein-Molho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandie","family":"Heald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Hatchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Esplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6745-1733","authenticated-orcid":false,"given":"Eitan","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"6723_CR1","volume-title":"Ataxia Telangiectasia 2020. StatPearls [Internet]","author":"GM Riboldi","year":"2021","unstructured":"Riboldi GM, Samanta D, Frucht S (2021) Ataxia Telangiectasia 2020. StatPearls [Internet]. StatPearls Publishing, Treasure Island"},{"issue":"21","key":"6723_CR2","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJM198705213162101","volume":"316","author":"M Swift","year":"1987","unstructured":"Swift M, Reitnauer PJ, Morrell D, Chase CL (1987) Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 316(21):1289\u20131294. https:\/\/doi.org\/10.1056\/NEJM198705213162101","journal-title":"N Engl J Med"},{"issue":"7","key":"6723_CR3","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/sj.bjc.6690460","volume":"80","author":"N Janin","year":"1999","unstructured":"Janin N, Andrieu N, Ossian K, Laug\u00e9 A, Croquette M-F, Griscelli C et al (1999) Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br J Cancer 80(7):1042\u20131045","journal-title":"Br J Cancer"},{"issue":"11","key":"6723_CR4","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/jnci\/dji141","volume":"97","author":"D Thompson","year":"2005","unstructured":"Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A et al (2005) Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 97(11):813\u2013822. https:\/\/doi.org\/10.1093\/jnci\/dji141","journal-title":"J Natl Cancer Inst"},{"issue":"26","key":"6723_CR5","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1056\/NEJM199112263252602","volume":"325","author":"M Swift","year":"1991","unstructured":"Swift M, Morrell D, Massey RB, Chase CL (1991) Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325(26):1831\u20131836. https:\/\/doi.org\/10.1056\/NEJM199112263252602","journal-title":"N Engl J Med"},{"issue":"1","key":"6723_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","volume":"19","author":"MB Daly","year":"2021","unstructured":"Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM et al (2021) Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19(1):77\u2013102. https:\/\/doi.org\/10.6004\/jnccn.2021.0001","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"6723_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/cge.12710","volume":"90","author":"NJH van Os","year":"2016","unstructured":"van Os NJH, Roeleveld N, Weemaes CMR, Jongmans MCJ, Janssens GO, Taylor AMR et al (2016) Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin Genet 90(2):105\u2013117","journal-title":"Clin Genet"},{"issue":"12","key":"6723_CR8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/jmedgenet-2016-103839","volume":"53","author":"MC Southey","year":"2016","unstructured":"Southey MC, Goldgar DE, Winqvist R, Pylk\u00e4s K, Couch F, Tischkowitz M et al (2016) PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet 53(12):800\u2013811","journal-title":"J Med Genet"},{"key":"6723_CR9","doi-asserted-by":"publisher","first-page":"R73","DOI":"10.1186\/bcr2919","volume":"13","author":"DE Goldgar","year":"2011","unstructured":"Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB et al (2011) Rare variants in the\u00a0ATM gene and risk of breast cancer. Breast Cancer Res 13:R73. https:\/\/doi.org\/10.1186\/bcr2919","journal-title":"Breast Cancer Res"},{"issue":"9","key":"6723_CR10","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","volume":"3","author":"FJ Couch","year":"2017","unstructured":"Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J et al (2017) Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol 3(9):1190\u20131196","journal-title":"JAMA Oncol"},{"issue":"5","key":"6723_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J et al (2021) A population-based study of genes previously implicated in breast cancer. N Engl J Med 384(5):440\u2013451. https:\/\/doi.org\/10.1056\/NEJMoa2005936","journal-title":"N Engl J Med"},{"issue":"5","key":"6723_CR12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"L Dorling","year":"2021","unstructured":"Breast Cancer Association Consortium, Dorling L, Carvalho S, Allen J, Gonz\u00e1lez-Neira A, Luccarini C, Wahlstr\u00f6m C et al (2021) Breast cancer risk genes - association analysis in more than 113,000 women. N Engl J Med 384(5):428\u2013439. https:\/\/doi.org\/10.1056\/NEJMoa1913948","journal-title":"N Engl J Med"},{"issue":"4","key":"6723_CR13","doi-asserted-by":"publisher","first-page":"R401","DOI":"10.1186\/bcr806","volume":"6","author":"GJ Lindeman","year":"2004","unstructured":"Lindeman GJ, Hiew M, Visvader JE, Leary J, Field M, Gaff CL et al (2004) Frequency of the ATM IVS10-6T\u2192G variant in Australian multiple-case breast cancer families. Br Can Res 6(4):R401","journal-title":"Br Can Res"},{"issue":"3","key":"6723_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cancergen.2015.12.006","volume":"209","author":"Y Laitman","year":"2016","unstructured":"Laitman Y, Boker-Keinan L, Berkenstadt M, Liphsitz I, Weissglas-Volkov D, Ries-Levavi L et al (2016) The risk for developing cancer in Israeli ATM, BLM, and FANCC heterozygous mutation carriers. Can Genet 209(3):70\u201374","journal-title":"Can Genet"},{"issue":"3","key":"6723_CR15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3390\/genes11030314","volume":"11","author":"T Rantapero","year":"2020","unstructured":"Rantapero T, Wahlfors T, K\u00e4hler A, Hultman C, Lindberg J, Tammela TL et al (2020) Inherited DNA repair gene mutations in men with lethal prostate cancer. Genes (Basel) 11(3):314\u2013326. https:\/\/doi.org\/10.3390\/genes11030314","journal-title":"Genes (Basel)"},{"issue":"4","key":"6723_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41436-019-0720-x","volume":"22","author":"AH Nassar","year":"2020","unstructured":"Nassar AH, Abou Alaiwi S, AlDubayan SH, Moore N, Mouw KW, Kwiatkowski DJ et al (2020) Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. Genet Med 22(4):709\u2013718. https:\/\/doi.org\/10.1038\/s41436-019-0720-x","journal-title":"Genet Med"},{"issue":"8","key":"6723_CR17","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/ng.3342","volume":"47","author":"H Helgason","year":"2015","unstructured":"Helgason H, Rafnar T, Olafsdottir HS, Jonasson JG, Sigurdsson A, Stacey SN et al (2015) Loss-of-function variants in ATM confer risk of gastric cancer. Nat Genet 47(8):906\u2013910. https:\/\/doi.org\/10.1038\/ng.3342","journal-title":"Nat Genet"},{"issue":"38","key":"6723_CR18","doi-asserted-by":"publisher","first-page":"40953","DOI":"10.18632\/oncotarget.5944","volume":"6","author":"D-S Huang","year":"2015","unstructured":"Huang D-S, Tao H-Q, He X-J, Long M, Yu S, Xia Y-J et al (2015) Prevalence of deleterious ATM germline mutations in gastric cancer patients. Oncotarget 6(38):40953\u201340958","journal-title":"Oncotarget"},{"issue":"2","key":"6723_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","volume":"7","author":"NJ Samadder","year":"2021","unstructured":"Samadder NJ, Riegert-Johnson D, Boardman L, Rhodes D, Wick M, Okuno S et al (2021) Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol 7(2):230\u2013237. https:\/\/doi.org\/10.1001\/jamaoncol.2020.6252 (Erratum.In:doi:10.1001\/jamaoncol.2020.7373)","journal-title":"JAMA Oncol"},{"issue":"10","key":"6723_CR20","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/gim.2017.37","volume":"19","author":"K Nykamp","year":"2017","unstructured":"Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho Y-Y et al (2017) Sherloc: a comprehensive refinement of the ACMG\u2013AMP variant classification criteria. Genet Med 19(10):1105\u20131117","journal-title":"Genet Med"},{"issue":"1","key":"6723_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/ng958","volume":"32","author":"K Spring","year":"2002","unstructured":"Spring K, Ahangari F, Scott SP, Waring P, Purdie DM, Chen PC et al (2002) Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer. Nat Genet 32(1):185\u2013190. https:\/\/doi.org\/10.1038\/ng958","journal-title":"Nat Genet"},{"issue":"3","key":"6723_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/94.3.205","volume":"94","author":"G Chenevix-Trench","year":"2002","unstructured":"Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X et al (2002) Dominant negative ATM mutations in breast cancer families. J Nat Can Inst 94(3):205\u2013215","journal-title":"J Nat Can Inst"},{"issue":"1","key":"6723_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/gcc.20101","volume":"42","author":"E Cavaciuti","year":"2005","unstructured":"Cavaciuti E, Laug\u00e9 A, Janin N, Ossian K, Hall J, Stoppa-Lyonnet D et al (2005) Cancer risk according to type and location of ATM mutation in ataxia-telangiectasia families. Genes Chrom Can 42(1):1\u20139. https:\/\/doi.org\/10.1002\/gcc.20101","journal-title":"Genes Chrom Can"},{"issue":"5","key":"6723_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/gepi.21971","volume":"40","author":"M Marabelli","year":"2016","unstructured":"Marabelli M, Cheng S-C, Parmigiani G (2016) Penetrance of ATM gene mutations in breast cancer: a meta-analysis of different measures of risk. Genet Epidemiol 40(5):425\u2013431","journal-title":"Genet Epidemiol"},{"issue":"16","key":"6723_CR25","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1002\/cncr.32083","volume":"125","author":"J Weitzel","year":"2019","unstructured":"Weitzel J, Neuhausen SL, Adamson A, Tao S, Ricker C, Maoz A et al (2019) Pathogenic and likely pathogenic variants in PALB2, CHEK2 and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Cancer 125(16):2829\u20132836","journal-title":"Cancer"},{"issue":"1","key":"6723_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/jmedgenet-2019-106189","volume":"57","author":"F Fostira","year":"2020","unstructured":"Fostira F, Kostantopoulou I, Apostolou P, Papamentzelopoulou MS, Papadimitriou C, Faliakou E et al (2020) One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene. J Med Genet 57(1):53\u201361","journal-title":"J Med Genet"},{"issue":"4","key":"6723_CR27","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/ijc.30771","volume":"141","author":"S Lolas Hamameh","year":"2017","unstructured":"Lolas Hamameh S, Renbaum P, Kamal L, Dweik D, Salahat M, Jaraysa T et al (2017) Genomic analysis of inherited breast cancer among Palestinian women: genetic heterogeneity and a founder mutation in TP53. Int J Cancer 141(4):750\u2013756","journal-title":"Int J Cancer"},{"issue":"6","key":"6723_CR28","first-page":"1505","volume":"19","author":"J Soukupova","year":"2008","unstructured":"Soukupova J, Dundr P, Kleibl Z, Pohlreich P (2008) Contribution of mutations in ATM to breast cancer development in the Czech population. Oncol Rep 19(6):1505\u20131510","journal-title":"Oncol Rep"},{"issue":"4","key":"6723_CR29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1940-6207.CAPR-20-0448","volume":"14","author":"MJ Hall","year":"2021","unstructured":"Hall MJ, Bernhisel R, Hughes E, Larson K, Rosenthal ET, Singh NA et al (2021) Germline pathogenic variants in the Ataxia Telangiectasia Mutated (ATM) gene are associated with high and moderate risks for multiple cancers. Cancer Prev Res (Phila) 14(4):433\u2013440. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-20-0448","journal-title":"Cancer Prev Res (Phila)"},{"issue":"11","key":"6723_CR30","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1001\/jamaoncol.2021.3701","volume":"7","author":"FC Hsu","year":"2021","unstructured":"Hsu FC, Roberts NJ, Childs E, Porter N, Rabe KG, Borgida A et al (2021) Risk of pancreatic cancer among individuals with pathogenic variants in the ATM gene. JAMA Oncol 7(11):1664\u20131668. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3701","journal-title":"JAMA Oncol"},{"key":"6723_CR31","doi-asserted-by":"publisher","unstructured":"Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, et al (2020) International Cancer of the Pancreas Screening (CAPS) consortium. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 69(1):7\u201317. https:\/\/doi.org\/10.1136\/gutjnl-2019-319352. Erratum in: Gut. 2020; 69(6):e3","DOI":"10.1136\/gutjnl-2019-319352"},{"issue":"12","key":"6723_CR32","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.jtho.2020.08.017","volume":"15","author":"M Esai Selvan","year":"2020","unstructured":"Esai Selvan M, Zauderer MG, Rudin CM, Jones S, Mukherjee S, Offit K et al (2020) Inherited rare, deleterious variants in ATM increase lung adenocarcinoma risk. J Thor Oncol 15(12):1871\u20131879","journal-title":"J Thor Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06723-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06723-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06723-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T17:07:52Z","timestamp":1666199272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06723-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["6723"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06723-z","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"13 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sarah M. Nielsen, Brandie Heald, Kathryn E. Hatchell, and Edward D. Esplin are all employees of the Invitae corp. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest:"}},{"value":"The study was carried out in compliance with Western Institutional Review Board (WIRB) protocol number 1167406, which allows for study and publication of de-identified patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}